Company intelligence / Profile preview

Harm Reduction Therapeutics

Pittsburgh, Pennsylvania, United Statesharmreductiontherapeutics.org ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

Harm Reduction Therapeutics developed RiVive, a low-dose intranasal naloxone product for emergency treatment of opioid overdose. RiVive received FDA approval in July 2023 as an over-the-counter medication and became commercially available in the U.S. in early 2024. The product was developed to be affordable and accessible, with at least 10% of annual production donated to underfunded harm reduction organizations[3][7][9].

Therapeutic areas: Neurology
Modalities: Small molecule (naloxone)Device (intranasal spray)
Industry: Biotech

Drug pipeline

1 asset

naloxone

Commercial

Indications: Opioid overdose

Partnerships

Purdue Pharma (provided funding, technical expertise, and data; no operational or governance role)[8][9]

Beyond the preview

Go deeper on Harm Reduction Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harm Reduction Therapeutics.

Explore the full profile